Amyloid-β 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials

Published on Aug 25, 2015in Neurology8.689
· DOI :10.1212/WNL.0000000000001877
Enchi Liu15
Estimated H-index: 15
Mark E. Schmidt21
Estimated H-index: 21
+ 20 AuthorsH. Robert Brashear15
Estimated H-index: 15
Objective: To evaluate the effects of bapineuzumab on brain β-amyloid (Aβ) burden using 11 C-Pittsburgh compound B ( 11 C-PiB)-PET. Methods: Two phase 3 clinical trials, 1 each in apolipoprotein APOE e4 carriers and noncarriers, were conducted in patients with mild to moderate Alzheimer disease dementia. Bapineuzumab, an anti-Aβ monoclonal antibody, or placebo, was administered by IV infusion every 13 weeks for 78 weeks. PET substudies assessed change in brain fibrillar Aβ over 71 weeks using an 11 C-PiB-PET standardized uptake value ratio (SUVr) global cortical average (GCA) comprising the average SUVr from 5 cortical regions of interest with cerebellar gray matter as the reference region. Results: A total of 115 carriers and 39 noncarriers were analyzed. The difference (δ) in mean baseline to 71 week change in 11 C-PiB-PET GCA between bapineuzumab and placebo was significant in carriers (0.5 mg/kg vs placebo δ = −0.101; p = 0.004) and in pooled analyses of both carriers and noncarriers (0.5 mg/kg vs placebo δ = −0.068; p = 0.027; 1.0 mg/kg vs placebo δ = −0.133; p = 0.028) but not in the noncarrier trial separately. Analyses by individual region of interest and in mild disease yielded findings similar to the main trial results. Conclusions: The 11 C-PiB-PET imaging results demonstrated reduction of fibrillar Aβ accumulation in patients with Alzheimer disease treated with bapineuzumab; however, as no clinical benefit was observed, the findings are consistent with the hypotheses that bapineuzumab may not have been initiated early enough in the disease course, the doses were insufficient, or the most critical Aβ species were inadequately targeted.
  • References (20)
  • Citations (72)
📖 Papers frequently viewed together
895 Citations
819 Citations
28 Authors (Jeff Sevigny, ..., Alfred Sandrock)
632 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
#1Mark E. Schmidt (Janssen Pharmaceutica)H-Index: 21
#2Ping Chiao (Biogen Idec)H-Index: 7
Last. William J. Jagust (HWNI: Helen Wills Neuroscience Institute)H-Index: 53
view all 14 authors...
Abstract In vivo imaging of amyloid burden with positron emission tomography (PET) provides a means for studying the pathophysiology of Alzheimer's and related diseases. Measurement of subtle changes in amyloid burden requires quantitative analysis of image data. Reliable quantitative analysis of amyloid PET scans acquired at multiple sites and over time requires rigorous standardization of acquisition protocols, subject management, tracer administration, image quality control, and image process...
41 CitationsSource
#1Rachelle S. Doody (BCM: Baylor College of Medicine)H-Index: 60
#2Ronald G. Thomas (UCSD: University of California, San Diego)H-Index: 53
Last. Richard C. Mohs (UCSD: University of California, San Diego)H-Index: 66
view all 13 authors...
819 CitationsSource
#1Stephen Salloway (Brown University)H-Index: 55
#2Reisa A. Sperling (Harvard University)H-Index: 90
Last. H. Robert Brashear (Janssen Pharmaceutica)H-Index: 15
view all 24 authors...
895 CitationsSource
#1Keith Johnson (Harvard University)H-Index: 88
#2Reisa A. Sperling (Harvard University)H-Index: 90
Last. Daniel Skovronsky (Avid Radiopharmaceuticals)H-Index: 15
view all 19 authors...
Abstract Objective To evaluate the performance characteristics of florbetapir F18 positron emission tomography (PET) in patients with Alzheimer's disease (AD), mild cognitive impairment (MCI), and healthy control subjects (HCs). Methods Florbetapir PET was acquired in 184 subjects (45 AD patients, 60 MCI patients, and 79 HCs) within a multicenter phase 2 study. Amyloid burden was assessed visually and quantitatively, and was classified as positive or negative. Results Florbetapir PET was rated v...
110 CitationsSource
#1Kaj BlennowH-Index: 123
#2Henrik ZetterbergH-Index: 90
Last. InvestigatorsH-Index: 1
view all 9 authors...
Background Given the slow and variable clinical course of Alzheimer disease, very large and extended clinical trials are needed to identify a beneficial clinical effect of disease-modifying treatments. Therefore, biomarkers are essential to prove that an anti–β-amyloid (Aβ) drug candidate affects both Aβ metabolism and plaque load as well as downstream pathogenic mechanisms. Objective To evaluate the effect of the anti-Aβ monoclonal antibody bapineuzumab on cerebrospinal fluid (CSF) biomarkers r...
169 CitationsSource
#1Susanne OstrowitzkiH-Index: 14
#2Dennis DeptulaH-Index: 6
Last. Luca SantarelliH-Index: 15
view all 12 authors...
Background Gantenerumab is a fully human anti-Aβ monoclonal antibody in clinical development for the treatment of Alzheimer disease (AD). Objectives To investigate whether treatment with gantenerumab leads to a measurable reduction in the level of Aβ amyloid in the brain and to elucidate the mechanism of amyloid reduction. Design A multicenter, randomized, double-blind, placebo-controlled, ascending-dose positron emission tomographic study. Additionally, ex vivo studies of human brain slices fro...
287 CitationsSource
#1Manuel Jorge Cardoso (UCL: University College London)H-Index: 30
#2Matthew J. Clarkson (UCL: University College London)H-Index: 20
Last. Sebastien Ourselin (UCL: University College London)H-Index: 62
view all 6 authors...
Abstract Thickness measurements of the cerebral cortex can aid diagnosis and provide valuable information about the temporal evolution of diseases such as Alzheimer's, Huntington's, and schizophrenia. Methods that measure the thickness of the cerebral cortex from in-vivo magnetic resonance (MR) images rely on an accurate segmentation of the MR data. However, segmenting the cortex in a robust and accurate way still poses a challenge due to the presence of noise, intensity non-uniformity, partial ...
80 CitationsSource
#1Henryk Barthel (Leipzig University)H-Index: 37
#2Hermann-Josef Gertz (Leipzig University)H-Index: 30
Last. Osama Sabri (Leipzig University)H-Index: 41
view all 11 authors...
Summary Background Imaging with amyloid-β PET can potentially aid the early and accurate diagnosis of Alzheimer's disease. Florbetaben ( 18 F) is a promising 18 F-labelled amyloid-β-targeted PET tracer in clinical development. We aimed to assess the sensitivity and specificity of florbetaben ( 18 F) PET in discriminating between patients with probable Alzheimer's disease and elderly healthy controls. Methods We did a multicentre, open-label, non-randomised phase 2 study in 18 centres in Australi...
299 CitationsSource
#1Timo Grimmer (LMU: Ludwig Maximilian University of Munich)H-Index: 31
#2Susanne Tholen (LMU: Ludwig Maximilian University of Munich)H-Index: 4
Last. Alexander Drzezga (LMU: Ludwig Maximilian University of Munich)H-Index: 28
view all 13 authors...
Background Pittsburgh Compound B ([ 11 C] PiB) is a specific positron emission tomography (PET) marker of cerebral amyloid deposits. Only few data have been published on in vivo longitudinal changes of amyloid load in Alzheimer's disease (AD) patients, with conflicting results. Therefore, little is known about the factors that influence these changes. Methods A group of 24 patients with probable AD diagnosed by combining established clinical criteria with an AD-typical pattern in [ 18 F] fluoro-...
73 CitationsSource
#1Marc Modat (UCL: University College London)H-Index: 34
#2Gerard R. Ridgway (UCL Institute of Neurology)H-Index: 40
Last. Sebastien Ourselin (UCL Institute of Neurology)H-Index: 62
view all 8 authors...
A large number of algorithms have been developed to perform non-rigid registration and it is a tool commonly used in medical image analysis. The free-form deformation algorithm is a well-established technique, but is extremely time consuming. In this paper we present a parallel-friendly formulation of the algorithm suitable for graphics processing unit execution. Using our approach we perform registration of T1-weighted MR images in less than 1min and show the same level of accuracy as a classic...
514 CitationsSource
Cited By72
#1Alexandra Oxford (BSU: Boise State University)
#2Erica S. Stewart (BSU: Boise State University)
Last. Troy T. Rohn (BSU: Boise State University)H-Index: 26
view all 3 authors...
Human clinical trials seek to ameliorate the disease states and symptomatic progression of illnesses that, as of yet, are largely untreatable according to clinical standards. Ideally, clinical trials test “disease-modifying drugs,” i.e., therapeutic agents that specifically modify pathological features or molecular bases of the disease and would presumably have a large impact on disease progression. In the case of Alzheimer’s disease (AD), however, this approach appears to have stalled progress ...
#1Tengfei Guo (LBNL: Lawrence Berkeley National Laboratory)H-Index: 1
Last. William J. JagustH-Index: 95
view all 3 authors...
OBJECTIVE: To examine the feasibility of using cross-sectional PET to identify cognitive decliners among beta-amyloid (Abeta)-negative cognitively normal (CN) elderly adults. METHODS: We determined the highest Abeta-affected region by ranking baseline and accumulation rates of florbetapir-PET regions in 355 CN elderly adults using (18)F-florbetapir-PET from the Alzheimer's Disease Neuroimaging Initiative (ADNI). The banks of the superior temporal sulcus (BANKSSTS) were found as the highest Abeta...
1 CitationsSource
#1Christopher D. Morrone (Sunnybrook Research Institute)H-Index: 2
#2Jossana Bishay (U of T: University of Toronto)H-Index: 1
Last. JoAnne McLaurin (U of T: University of Toronto)H-Index: 36
view all 3 authors...
Insurmountable evidence has demonstrated a strong association between Alzheimer’s disease (AD) and cerebral amyloid angiopathy (CAA), along with various other cerebrovascular diseases. One form of CAA, which is the accumulation of amyloid-beta peptides (Aβ) along cerebral vessel walls, impairs perivascular drainage pathways and contributes to cerebrovascular dysfunction in AD. To date, CAA research has been primarily focused on arterial Aβ, while the accumulation of Aβ in veins and venules were ...
#1Georgia R. Frost (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 1
#2Lauren A. Jonas (Cornell University)H-Index: 1
Last. Yue-Ming Li (Cornell University)H-Index: 3
view all 3 authors...
Alzheimer’s disease (AD) is marked by the presence of amyloid beta (Aβ) plaques, neurofibrillary tangles (NFT), neuronal death and synaptic loss, and inflammation in the brain AD research has, in large part, been dedicated to the understanding of Aβ and NFT deposition as well as to the pharmacological reduction of these hallmarks. However, recent GWAS data indicates neuroinflammation plays a critical role in AD development, thereby redirecting research efforts towards unveiling the complexities ...
3 CitationsSource
#1Zongjun Guo (Qingdao University)
#2Xing Peng (CAS: Chinese Academy of Sciences)H-Index: 5
Last. Hongxing Lei (CAS: Chinese Academy of Sciences)H-Index: 22
view all 12 authors...
#1Jeffrey L. Cummings (Cleveland Clinic)H-Index: 135
#2Howard Feldman (UCSD: University of California, San Diego)H-Index: 69
Last. Philip Scheltens (UvA: University of Amsterdam)H-Index: 116
view all 3 authors...
There is a high rate of failure in Alzheimer’s disease (AD) drug development with 99% of trials showing no drug-placebo difference. This low rate of success delays new treatments for patients and discourages investment in AD drug development. Studies across drug development programs in multiple disorders have identified important strategies for decreasing the risk and increasing the likelihood of success in drug development programs. These experiences provide guidance for the optimization of AD ...
Abstract Correctly diagnosing early symptomatic Alzheimer's disease in the context of multinational clinical trials poses a significant challenge. Subjective complaints of memory ae fairly ubiquitous in an older population, and establishing the presence of definitive cognitive decline from clinical assessments is difficult. Most such trials have adopted the use of standardized episodic memory measures as an inclusion criterion, typically setting the cutoff at one standard deviation below age nor...
#1Yannick ChantranH-Index: 3
#2Jean CapronH-Index: 3
Last. Pierre AucouturierH-Index: 43
view all 4 authors...
Cerebral amyloid angiopathy (CAA) corresponds to the deposition of amyloid material in the cerebral vasculature, leading to structural modifications of blood vessel walls. The most frequent form of sporadic CAA involves fibrillar β-amyloid peptide (Aβ) deposits, mainly the 40 amino acid form (Aβ1-40), which are commonly found in the elderly with or without Alzheimer's disease. Sporadic CAA usually remains clinically silent. However, in some cases, acute complications either hemorrhagic or inflam...
#1James A. R. Nicoll (University of Southampton)H-Index: 57
#2George R. Buckland (University of Southampton)H-Index: 1
Last. Delphine Boche (University of Southampton)H-Index: 25
view all 9 authors...
6 CitationsSource
#1Anupamjeet Kaur (Sri Guru Granth Sahib World University)H-Index: 2
#2Sukhmani Mann (Sri Guru Granth Sahib World University)H-Index: 3
Last. Deepti Goyal (Sri Guru Granth Sahib World University)H-Index: 4
view all 7 authors...
Abstract A novel series of triazole-based compounds have been designed, synthesised and evaluated as multi-target-directed ligands (MTDLs) against Alzheimer disease (AD). The triazole-based compounds have been designed to target four major AD hallmarks that include Aβ aggregation, metal-induced Aβ aggregation, metal dys-homeostasis and oxidative stress. Among the synthesised compounds, 6n having o-CF3 group on the phenyl ring displayed most potent inhibitory activity (96.89% inhibition, IC50 = 8...
4 CitationsSource